Inhibikase Therapeutics I...

NASDAQ: IKT · Real-Time Price · USD
1.84
0.13 (7.60%)
At close: Aug 15, 2025, 3:00 PM

Inhibikase Therapeutics Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Income
-27.52M -19.03M -18.05M -14.79M
Depreciation & Amortization
26.27K 177.4K 6.72K n/a
Stock-Based Compensation
8.14M 500.15K 458.15K 1.53M
Other Working Capital
-66.85K 699.28K 39.53K -2.33M
Other Non-Cash Items
n/a 31.54K 67K 721.63K
Deferred Income Tax
n/a n/a n/a n/a
Change in Working Capital
204.93K 234.76K 171.18K -1.76M
Operating Cash Flow
-19.15M -18.09M -17.35M -14.3M
Capital Expenditures
n/a -14.24K -243.25K n/a
Cash Acquisitions
n/a n/a 243.25K n/a
Purchase of Investments
-60.46M -29.43M -20.73M n/a
Sales Maturities Of Investments
23.45M 41.1M 4.96M n/a
Other Investing Acitivies
n/a n/a -243.25K n/a
Investing Cash Flow
-37M 11.66M -16.01M n/a
Debt Repayment
n/a n/a -248.91K -42.53K
Common Stock Repurchased
n/a n/a n/a n/a
Dividend Paid
n/a n/a n/a n/a
Other Financial Acitivies
n/a n/a n/a 848.00
Financial Cash Flow
103.48M 8.41M -204.77K 41.09M
Net Cash Flow
47.33M 1.98M -33.56M 26.8M
Free Cash Flow
-19.15M -18.1M -17.59M -14.3M